跳至主要内容
临床试验/NCT06342999
NCT06342999Enrolling By Invitation不适用

Evaluation of Outcomes of Fetal Aortic Valvuloplasty for Evolving Hypoplastic Left Heart Syndrome

Mauro H. Schenone2 个研究点 分布在 1 个国家目标入组 80 人开始时间: 2027年1月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
Enrolling By Invitation
发起方
入组人数
80
试验地点
2
主要终点
Number of cases in which the procedure was successful

研究概览

简要总结

The purpose of this research is to investigate the best way to manage evolving hypoplastic left heart syndrome (HLHS).

详细描述

The condition occurs when part of the heart doesn't develop properly so the heart is not able to pump blood around the body effectively. Babies born with this condition require surgery and are often left with a lifelong heart disability. A number of babies with this condition will die during pregnancy or within the first year of life (approximately 10-40%). We are investigating a treatment given during pregnancy in which a balloon is used to increase the size of the baby's aortic valve. The aortic valve function is to allow easy flow from the heart to the body and prevent blood from returning to the heart (regurgitation). This is called fetal aortic valvuloplasty. A number of studies have shown promising results, including a higher of the baby surviving with both sides of the heart functioning (as opposed to only the right side), this may also lead to longer survival with a better quality of life. However, we do not have enough information to say this is always the best way to manage the condition. Currently, parents of babies with this condition, who meet certain eligibility criteria, are offered fetal aortic valvuloplasty during pregnancy. The alternative option is not to intervene during pregnancy but instead monitor the baby with regular ultrasounds. We call this conservative management.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
— 至 45 Years(Child, Adult)
性别
Female
接受健康志愿者

入选标准

  • Pregnant women 18-45 years of age.
  • Gestational age between 21 0/7 and 29 6/7 weeks of gestation
  • The mother must be healthy enough to undergo surgery.
  • The individual being enrolled must be able to provide informed consent.
  • Dominant cardiac defect is valvar
  • Evolving hypoplastic left heart syndrome defined as depressed left ventricle systolic and at least one of the following:
  • Retrograde flow in the transverse aortic arch
  • Two of the following: (1) left to right flow across the atrial septum (bulging of the septum left to right in cases of intact atrial septum); (2) monophasic mitral valve inflow; (3) bidirectional flow in the pulmonary veins.
  • Potential for a technically successful and postnatal biventricular outcome defined as left ventricle long axis Z-score equal or greater than -2 PLUS at least 4 of the following 5 criteria:
  • Left ventricle long axis Z-score more than zero
  • Left ventricle short axis Z-score more than zero
  • Aortic annulus Z-score more than -3.5
  • Mitral valve annulus Z-score more than -2
  • Left ventricle generating a maximal instantaneous gradient (MIG) equal or greater than 20 mmHg (or by mitral regurgitation jet greater than or equal to 20 mmHg).

排除标准

  • Patient is less than 18 years of age or more than 45 years of age.
  • Contraindication to anesthesia or surgery
  • Preterm labor or cervical length <20 mm at enrollment or uterine anomaly strongly predisposing to preterm delivery.
  • Other fetal anomalies that significantly impact fetal/neonatal survival (e.g., congenital diaphragmatic hernia, bilateral renal agenesis, etc.)
  • Fetal aneuploidy and pathogenic findings on Karyotype or Microarray that impact significantly the fetal/neonatal survival.
  • Cases with all the following criteria:
  • Left ventricle pressure ≤ 47 mmHg
  • MV dimension Z-score < 0.1
  • MV inflow time Z-score < -2

研究组 & 干预措施

Intervention Group: Fetal Aortic Valvuloplasty

Experimental

Women diagnosed with HLHS will undergo fetal aortic valvuloplasty between 21 and 29 weeks gestation.

干预措施: Trek RX and Mini Trek RX Coronary Dilatation Catheter (Device)

Control Group: Expectant Management

No Intervention

Women diagnosed with HLHS will undergo expectant management with postnatal surgery.

Intervention Group: Fetal Aortic Valvuloplasty

Experimental

Women diagnosed with HLHS will undergo fetal aortic valvuloplasty between 21 and 29 weeks gestation.

干预措施: Fetal Aortic Valvuloplasty Procedure (Procedure)

Intervention Group: Fetal Aortic Valvuloplasty

Experimental

Women diagnosed with HLHS will undergo fetal aortic valvuloplasty between 21 and 29 weeks gestation.

干预措施: Emerge Monorail and Over-The-Wire PTCA Dilatation Catheter (Device)

结局指标

主要结局

Number of cases in which the procedure was successful

时间窗: Baseline

Procedure success defined as the aortic valve was crossed and the balloon inflated with clear evidence of improvement of blood flow through the aortic valve and or new aortic valve regurgitation

Number of cases in which a biventricular repair was achieved

时间窗: Baseline

Number cases with pulmonary hypertension

时间窗: Baseline

次要结局

  • Number of cases with perinatal death(Baseline)
  • Number of maternal complications(Baseline)
  • Number of cases delivered prematurely(Baseline)

研究者

发起方
Mauro H. Schenone
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Mauro H. Schenone

Regulatory Sponsor and Principal Investigator

Mayo Clinic

研究点 (2)

Loading locations...

相似试验